<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Felodipine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01023</strong>&#160; (APRD00374)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (<span class="caps">CCB</span>)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent <span class="caps">CCB</span> in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01023/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01023/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01023.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01023.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01023.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01023.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01023.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01023">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Felodipina</td><td>Spanish</td><td>INN</td></tr><tr><td>Felodipine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, BAN, USAN</td></tr><tr><td>Felodipinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Felodur ER</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Felogard</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Penedil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Plendil</td><td>AstraZeneca</td></tr><tr><td>Plendil Depottab</td><td>AstraZeneca</td></tr><tr><td>Plendil ER</td><td>AstraZeneca</td></tr><tr><td>Plendil Retard</td><td>AstraZeneca</td></tr><tr><td>Renedil</td><td>Sanofi-Aventis</td></tr><tr><td>Splendil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Lexxel</td><td>felodipine + enalapril maleate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/anti-arrhythmia-agents">Anti-Arrhythmia Agents</a></li>
<li><a href="/mesh/vasodilator-agents">Vasodilator Agents</a></li>
<li><a href="/mesh/calcium-channel-blockers">Calcium Channel Blockers</a></li>
<li><a href="/mesh/dihydropyridines">Dihydropyridines</a></li></ul></td></tr><tr><th>CAS number</th><td>72509-76-3</td></tr><tr><th>Weight</th><td>Average: 384.254<br>Monoisotopic: 383.069113515</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>19</sub>Cl<sub>2</sub>NO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>RZTAMFZIAATZDJ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pyridines and Derivatives</td></tr><tr><th>Subclass</th><td>Hydropyridines</td></tr><tr><th>Direct parent</th><td>Dihydropyridinecarboxylic Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Dichlorobenzenes; Aryl Chlorides; Dicarboxylic Acids and Derivatives; Carboxylic Acid Esters; Enamines; Enolates; Polyamines; Ethers; Organochlorides</td></tr><tr><th>Substituents</th><td>1,2-dichlorobenzene; chlorobenzene; aryl halide; benzene; dicarboxylic acid derivative; aryl chloride; carboxylic acid ester; enamine; carboxylic acid derivative; polyamine; ether; enolate; organochloride; organonitrogen compound; organohalogen</td></tr><tr><th>Classification description</th><td>This compound belongs to the dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of mild to moderate essential hypertension. </td></tr><tr><th>Pharmacodynamics</th><td>Felodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor.  Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.</td></tr><tr><th>Mechanism of action</th><td>Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.</td></tr><tr><th>Absorption</th><td>Is completely absorbed from the gastrointestinal tract; however, extensive first-pass metabolism through the portal circulation results in a low systemic availability of 15%. Bioavailability is unaffected by food. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>10 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>99%, primarily to the albumin fraction. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic metabolism primarily via cytochrome P450 3A4. Six metabolites with no appreciable vasodilatory effects have been identified. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Felodipine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00368">dehydrofelodipine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/370">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Although higher concentrations of the metabolites are present in the plasma due to decreased urinary excretion, these are inactive. Animal studies have demonstrated that felodipine crosses the blood-brain barrier and the placenta.</td></tr><tr><th>Half life</th><td>17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.8 L/min [Young healthy subjects]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly bradycardia. Oral rat LD<sub>50</sub> is 1050 mg/kg.
</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Felodipine Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00377?highlight%5Bcompounds%5D%5B%5D=DB01023&amp;highlight%5Bproteins%5D%5B%5D=DB01023">SMP00377</a></td></tr><tr><td>Felodipine Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00619?highlight%5Bcompounds%5D%5B%5D=DB01023&amp;highlight%5Bproteins%5D%5B%5D=DB01023">SMP00619</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9878</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.83</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5149</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8563</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8383</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8664</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8357</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6954</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8948</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9232</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7959</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.9304</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7849
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7511
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9527
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4526 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9455
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8734
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Astrazeneca pharmaceuticals lp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Heartland Repack Services LLC</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Mutual Pharmaceutical Co.</li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.richmondpharmacy.ca">Richmond Pharmacy</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, extended release</td><td>Oral</td><td>10 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>2.5 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>5 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Plendil 10 mg 24 Hour tablet</td><td>3.17USD</td><td>tablet</td></tr><tr><td>Plendil er 10 mg tablet</td><td>3.05USD</td><td>tablet</td></tr><tr><td>Plendil 10 mg tablet sa</td><td>2.96USD</td><td>tablet</td></tr><tr><td>Felodipine 10 mg 24 Hour tablet</td><td>2.95USD</td><td>tablet</td></tr><tr><td>Plendil er 2.5 mg tablet</td><td>2.94USD</td><td>tablet</td></tr><tr><td>Felodipine er 10 mg tablet</td><td>2.72USD</td><td>tablet</td></tr><tr><td>Plendil er 5 mg tablet</td><td>2.6USD</td><td>tablet</td></tr><tr><td>Plendil 5 mg 24 Hour tablet</td><td>1.77USD</td><td>tablet</td></tr><tr><td>Plendil 2.5 mg 24 Hour tablet</td><td>1.76USD</td><td>tablet</td></tr><tr><td>Felodipine 5 mg 24 Hour tablet</td><td>1.67USD</td><td>tablet</td></tr><tr><td>Plendil 2.5 mg tablet sa</td><td>1.65USD</td><td>tablet</td></tr><tr><td>Plendil 5 mg tablet sa</td><td>1.65USD</td><td>tablet</td></tr><tr><td>Felodipine 2.5 mg 24 Hour tablet</td><td>1.57USD</td><td>tablet</td></tr><tr><td>Felodipine er 2.5 mg tablet</td><td>1.51USD</td><td>tablet</td></tr><tr><td>Felodipine er 5 mg tablet</td><td>1.51USD</td><td>tablet</td></tr><tr><td>Renedil 10 mg Extended-Release Tablet</td><td>1.22USD</td><td>tablet</td></tr><tr><td>Plendil 10 mg Extended-Release Tablet</td><td>1.15USD</td><td>tablet</td></tr><tr><td>Renedil 5 mg Extended-Release Tablet</td><td>0.81USD</td><td>tablet</td></tr><tr><td>Plendil 5 mg Extended-Release Tablet</td><td>0.77USD</td><td>tablet</td></tr><tr><td>Sandoz Felodipine 10 mg Extended-Release Tablet</td><td>0.73USD</td><td>tablet</td></tr><tr><td>Renedil 2.5 mg Extended-Release Tablet</td><td>0.6USD</td><td>tablet</td></tr><tr><td>Plendil 2.5 mg Extended-Release Tablet</td><td>0.57USD</td><td>tablet</td></tr><tr><td>Sandoz Felodipine 5 mg Extended-Release Tablet</td><td>0.48USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>145 &#176;C</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>19.7 mg/L</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>3.86</td><td>SANGSTER (1994)</td></tr><tr><td>Caco2 permeability</td><td>-4.64</td><td>ADME Research, USCD</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>7.15e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.36</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.44</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.7</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>5.39</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>64.63</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>99.2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>38.04</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Vinay Sharma, &#8220;Preparation of micron-size felodipine particles by microfluidization.&#8221; U.S. Patent US20020086061, issued July 04, 2002.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20020086061&amp;tbm=pts" target="_blank">US20020086061 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Dunselman PH, Edgar B: Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1782737">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00319" target="_blank">D00319 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3333" target="_blank">3333 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506968" target="_blank">46506968 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.3216.html" target="_blank">3216 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50017710" target="_blank">50017710 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=585948" target="_blank">585948 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1480" target="_blank">CHEMBL1480 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000487" target="_blank">DAP000487 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449591" target="_blank">PA449591 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=4190" target="_blank">4190 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4190" target="_blank">4190 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2222000" target="_blank">2222000 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/felo.htm" target="_blank">http://www.rxlist.com/cgi/generic2/felo.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/felodipine.html" target="_blank">http://www.drugs.com/cdi/felodipine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=ple1339.html&amp;contentName=Plendil&amp;contentId=593" target="_blank">http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=ple1339.html&amp;contentName=Plendil&amp;contentId=593 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Felodipine" target="_blank">Felodipine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C08CA02<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C08#C08">C08 &#8212; CALCIUM CHANNEL BLOCKERS</a></li><li><a href="/atc/C08C#C08C">C08C &#8212; SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS</a></li><li><a href="/atc/C08CA#C08CA">C08CA &#8212; Dihydropyridine derivatives</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:28.08</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01023.pdf?1265922813">show</a>(228 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB01023.pdf?1265922749">show</a>(55.4 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01351">Amobarbital</a></td><td>The barbiturate, amobarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB01352">Aprobarbital</a></td><td>The barbiturate, aprobarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00237">Butabarbital</a></td><td>The barbiturate, butabarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>The barbiturate, butalbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB01353">Butethal</a></td><td>The barbiturate, butethal, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may increase the metabolism of felodipine. Monitor for changes in the therapeutic and adverse effects of felodipine if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>The barbiturate, dihydroquinidine barbiturate, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Erythromycin increases the effect of felodipine</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The hydantoin decreases the effect of felodipine</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The hydantoin decreases the effect of felodipine</td></tr><tr><td><a href="/drugs/DB01354">Heptabarbital</a></td><td>The barbiturate, heptabarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB01355">Hexobarbital</a></td><td>The barbiturate, hexobarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase the therapeutic and adverse effects of felodipine.</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>Erythromycin increases the effect of felodipine</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The hydantoin decreases the effect of felodipine</td></tr><tr><td><a href="/drugs/DB00474">Methohexital</a></td><td>The barbiturate, methohexital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00849">Methylphenobarbital</a></td><td>The barbiturate, methylphenobarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir increases the effect and toxicity of felodipine</td></tr><tr><td><a href="/drugs/DB00776">Oxcarbazepine</a></td><td>Oxcarbazepine decreases the levels of felodipine</td></tr><tr><td><a href="/drugs/DB00312">Pentobarbital</a></td><td>The barbiturate, pentobarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>The barbiturate, phenobarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The hydantoin decreases the effect of felodipine</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>The barbiturate, primidone, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>The barbiturate, quinidine barbiturate, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00418">Secobarbital</a></td><td>The barbiturate, secobarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Felodipine increases tacrolimus levels</td></tr><tr><td><a href="/drugs/DB00306">Talbutal</a></td><td>The barbiturate, talbutal, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Felodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felodipine if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00599">Thiopental</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Felodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Felodipine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may alter the concentration of Felopidine. Monitor for efficacy and adverse/toxic effects of Felopidine.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The moderate CYP2C8 inhibitor, Felopidine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Felopidine is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felodipine if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication. </li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>